THE EFFICACY AND SAFETY OF IMMARD (HYDROXYCHLOROQUINE) IN RHEUMATOID ARTHRITIS ACCORDING TO THE DATA OF AN OPEN-LABEL UNCONTROLLED TRIAL IN OUTPATIENT PRACTICE
https://doi.org/10.14412/1995-4484-2012-1292
Abstract
Objective: to evaluate the efficacy and safety of immard in rheumatoid arthritis (RA) in outpatient practice. Subjects and methods. The open-labeled uncontrolled trial enrolled 30 patients with the reliable and valid diagnosis of RA of varying duration. Immard was used in patients with early RA or as an additive agent when a disease-modifying anti-rheumatic drug (mainly methotrexate) was ineffective. The effect of immard was evaluated 3 months of its intake of 400 mg from the number of swollen and tender joints, patients' and physicians' total ratings of disease activity on a visual analogue scale, from ESR values, C-reactive protein (CRP) levels, and DAS28 scores. Results. There was a significant decrease in the number of swollen joints and DAS28 scores in the patients receiving a combination of methotrexate and immard. No significant reduction in ERS and CRP levels was revealed during the follow-up period.
References
1. <div><p>Clark P., Casas E., Tugwell P. et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993; 119: 1067-71.</p><p>Tsakonas E., Fitzgerald A.A., Fitzgerald M.A. et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheum 2000; 27(3): 623-8.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 Recommendations for the use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthr Care Res 2008; 59: 762-84.</p><p>Чичасова Н.В., Имаметдинова Г.Р., Насонов Е.Л. Место плаквенила в современной терапии ревматоидного артрита. Рус. мед. журн. 2009; 17(7): 487—90.</p><p>Сергиец Н.А., Еров Н.К. Комбинированная базисная терапия ревматоидного артрита метотрексатом и плаквенилом. Науч.-практич. ревматол. 2009; 1: 30-4.</p><p>Губарь Е.Е., Бочкова А.Г., Бунчук Н.В. Сравнение эффективности и переносимости тройной базисной терапии (метотрексат + сульфасалазин + гидроксихлорохин) с монотерапией метотрексатом у больных ревматоидным артритом. Тер. арх. 2008; 5: 26-30.</p></div><br />
Review
For citations:
Balabanova R.M., Gukasyan D.A., Shakhramanova E.L., Goryachev D.V. THE EFFICACY AND SAFETY OF IMMARD (HYDROXYCHLOROQUINE) IN RHEUMATOID ARTHRITIS ACCORDING TO THE DATA OF AN OPEN-LABEL UNCONTROLLED TRIAL IN OUTPATIENT PRACTICE. Rheumatology Science and Practice. 2012;50(6):42-44. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1292
Views:
13176
Email this article 